BGNE BeiGene, Ltd. Sponsored ADR

  1. Stocks
  2. Healthcare
  3. NASDAQ: BGNE

Price (delayed)

$254.62

Market cap

$23.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$21.97B

Sector: Healthcare
Industry: Biotechnology
Website: http://www.beigene.com
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Highlights

The equity has soared by 69% from the previous quarter
BeiGene's quick ratio has surged by 51% YoY and by 27% QoQ
The company's gross profit fell by 46% YoY but it rose by 25% QoQ
The revenue has contracted by 38% YoY but it has grown by 18% from the previous quarter
The net income has dropped by 82% year-on-year and by 8% since the previous quarter
The company's EPS fell by 46% YoY

Key stats

What are the main financial stats of BGNE
Market
Shares outstanding
91.08M
Market cap
$23.19B
Enterprise value
$21.97B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.38
Price to sales (P/S)
84.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
82.7
Earnings
Revenue
$265.67M
EBIT
-$1.52B
EBITDA
-$1.49B
Free cash flow
-$1.32B
Per share
EPS
-$1.56
Free cash flow per share
-$14.88
Book value per share
$47.33
Revenue per share
$3
TBVPS
$62.86
Balance sheet
Total assets
$5.57B
Total liabilities
$1.27B
Debt
$243.73M
Equity
$4.29B
Working capital
$4.32B
Liquidity
Debt to equity
0.06
Current ratio
7.69
Quick ratio
7.4
Net debt/EBITDA
0.82
Margins
EBITDA margin
-560.9%
Gross margin
74.6%
Net margin
-569.2%
Operating margin
-587.5%
Efficiency
Return on assets
-39.9%
Return on equity
-57.1%
Return on invested capital
-67.9%
Return on capital employed
-30.9%
Return on sales
-572.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BGNE stock price

How has the BeiGene stock price performed over time
Intraday
-10.94%
1 week
-7%
1 month
-14.13%
1 year
25.25%
YTD
53.61%
QTD
-11.11%

Financial performance

How have BeiGene's revenue and profit performed over time
Revenue
$265.67M
Gross profit
$198.1M
Operating income
-$1.56B
Net income
-$1.51B
Gross margin
74.6%
Net margin
-569.2%
BGNE's operating margin has dropped by 196% year-on-year but it is up by 8% since the previous quarter
BeiGene's net margin has plunged by 195% YoY but it has increased by 8% from the previous quarter
BeiGene's operating income has shrunk by 83% YoY and by 9% QoQ
The net income has dropped by 82% year-on-year and by 8% since the previous quarter

Growth

What is BeiGene's growth rate over time

Valuation

What is BeiGene stock price valuation
P/E
N/A
P/B
5.38
P/S
84.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
82.7
The company's EPS fell by 46% YoY
The equity has soared by 69% from the previous quarter
The price to book (P/B) is 16% lower than the last 4 quarters average of 6.4 and 2.2% lower than the 5-year quarterly average of 5.5
BGNE's price to sales (P/S) is 72% lower than its 5-year quarterly average of 302.9 but 63% higher than its last 4 quarters average of 51.9
The revenue has contracted by 38% YoY but it has grown by 18% from the previous quarter

Efficiency

How efficient is BeiGene business performance
The company's return on sales has shrunk by 188% YoY but it rose by 8% QoQ
BeiGene's ROIC has increased by 24% from the previous quarter
BGNE's return on equity is up by 22% since the previous quarter but it is down by 7% year-on-year
The company's return on assets rose by 18% QoQ

Dividends

What is BGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BGNE.

Financial health

How did BeiGene financials performed over time
The total assets has surged by 196% year-on-year and by 43% since the previous quarter
BGNE's total liabilities has surged by 116% year-on-year but it is down by 6% since the previous quarter
BeiGene's debt is 94% less than its equity
BeiGene's debt to equity has shrunk by 73% YoY and by 57% QoQ
BeiGene's debt has decreased by 33% from the previous quarter and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.